fix bad credit florida roofing contractor buy dvd movies online dvds movies online credit report repair fast credit repair bad credit car loans bad credit car loan

Register/Login


Get Updates Via Email






 Subscribe in a reader

Fight AntiSpam

Anti Spam Honeypot

Other Contributors

Srini Uppala
Want to contribute?

Hit Counter



Bookmarks

RSS Feeds


Add to Google
Add to My Yahoo!

- - - - - - - - - - - - - - - - - - - - - - - -
Add to Technorati Favorites
desi Blogs
View Pradeep Sadanapalli's profile on LinkedIn
Who links to me?

Sign My Guestbook

Sign my Guestbook from Bravenet.com 

« As safe as houses? Dutch history suggests not | Home | City buses to switch over to CNG soon »

Novartis to up Hyd headcount

Posted by Srini Uppala | January 29, 2008 | 693 views

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading ... Loading ...

Swiss-based multinational pharmaceutical company, Novartis, is planning to ramp up the manpower at its Hyderabad centre to 1,000 people from the present 300 in the next 18 months even as it has withheld R&D plans owing to its reservations about the Indian patent law.

The Hyderabad centre is mainly responsible for data mining, data warehousing and related processes.

Speaking to the media on Tuesday, Novartis India vice-chairman and managing director Ranjit Shahni said the company was still weighing options for starting R&D activities in India as they were apprehensive about the Indian patent law.

“We do not have any plans to set up an R&D centre in India. In fact, no global company will consider this as a right move as Indian patent laws are not WTO-compliant,” he said while stating that the headcount for the present operations in Hyderabad would be increased more than three-fold.

Shahni, who is in the city to take part in the International Leprosy Congress to be held from January 30 to February 4, said Novartis’ multi-drug therapy had helped cure about 4.5 million leprosy patients in the past seven years with donations amounting to $37 million.

The company also invests in TB, malaria and cancer eradication programmes.

SOURCES:
Business Standard

Topics: Job Matters |

Comments

You must be logged in to post a comment.